Description:
This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of
patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM
(ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).
Title
- Brief Title: (Apex) CGT9486 in Patients With Advanced Systemic Mastocytosis
- Official Title: A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis
Clinical Trial IDs
- ORG STUDY ID:
CGT9486-20-201
- SECONDARY ID:
2021-001010-10
- NCT ID:
NCT04996875
Conditions
- Advanced Systemic Mastocytosis (AdvSM)
- SM With an Associated Hematologic Neoplasm (SM-AHN)
- Mast Cell Leukemia (MCL)
- Aggressive Systemic Mastocytosis (ASM)
Interventions
Drug | Synonyms | Arms |
---|
CGT9486 tablets | PLX9486, bezuclastinib | CGT9486 |
Purpose
This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of
patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM
(ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).
Trial Arms
Name | Type | Description | Interventions |
---|
CGT9486 | Experimental | | |
Eligibility Criteria
Key Inclusion Criteria:
1. Diagnosed with 1 of the following advanced mastocytosis diagnoses by Eligibility
Committee:
1. Aggressive Systemic Mastocytosis (ASM)
2. Systemic Mastocytosis with an Associated Hematologic Neoplasm (SM-AHN)
3. Mast Cell Leukemia (MCL)
2. Measurable disease according to modified IWG-MRT-ECNM criteria
3. ECOG (0 to 3)
4. Have clinically acceptable local laboratory screening results (clinical chemistry,
hematology) within certain limits
Key Exclusion Criteria:
1. Persistent toxicity from previous therapy for Advanced Systemic Mastocytosis that has
not resolved to ≤ Grade 1
2. Associated hematologic neoplasm requiring immediate antineoplastic therapy
3. Clinically significant cardiac disease
4. Known positivity for the FIP1L1 PDGFRA fusion (Patients with eosinophilia without
detectable KIT D816V mutation must also lack the PDGFRA fusion mutation prior to
enrollment)
5. Seropositive for human immunodeficiency virus (HIV) 1 or 2, or positive for hepatitis
B surface antigen or hepatitis C virus (HCV) antibody
6. History of clinically significant bleeding event within 30 days before the first dose
of study drug or need for therapeutic anticoagulation on study
7. Diagnosed with or treated for malignancy other than the disease under study within the
prior 3 years before enrollment
8. Received any cytoreductive therapy or any investigational agent less than 14 days, and
for cladribine, interferon alpha, pegylated interferon, and any antibody therapy less
than 28 days, before screening bone marrow biopsy
9. Received hematopoietic growth factor support within 14 days before the first dose of
study drug
10. Received strong CYP3A4 inhibitors or inducers before the first dose of study drug
11. Need for treatment with steroids
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Determine the optimal dose of CGT9486 by safety assessments and response criteria |
Time Frame: | 18 months |
Safety Issue: | |
Description: | |
Secondary Outcome Measures
Measure: | Safety of CGT9486 as assessed by incidence of adverse events (AEs) |
Time Frame: | 18 months |
Safety Issue: | |
Description: | Incidence of AEs according to CTCAE version 5.0 or higher |
Measure: | Mutation allele burden |
Time Frame: | 18 months |
Safety Issue: | |
Description: | Percentage change in KIT D816V |
Measure: | Serum Tryptase |
Time Frame: | 18 months |
Safety Issue: | |
Description: | Percentage change in Serum Tryptase |
Measure: | Pharmacokinetic studies |
Time Frame: | 18 months |
Safety Issue: | |
Description: | Percentage change in plasma concentrations of CGT9486 |
Measure: | Change from baseline in histopathologic findings in blood and bone marrow |
Time Frame: | 18 months |
Safety Issue: | |
Description: | Percentage change in mast cell infiltration in the bone marrow and percentage change in eosinophilia and monocytosis in the blood |
Measure: | Change in spleen and liver volume by imaging |
Time Frame: | 18 months |
Safety Issue: | |
Description: | Percentage |
Measure: | Change in Patient Global Impression of Severity (PGIS) scale |
Time Frame: | 18 months |
Safety Issue: | |
Description: | 0 -10 points (higher values represent worse symptom outcomes) |
Measure: | Change in Patient Global Impression of Change (PGIC) scale |
Time Frame: | 18 months |
Safety Issue: | |
Description: | 0 - 7 points (higher values represent better symptom outcomes) |
Measure: | Change in Mastocytosis Quality of Life Questionnaire (MC-QoL) |
Time Frame: | 18 months |
Safety Issue: | |
Description: | 0 - 100 (higher values represent better symptom outcomes) |
Measure: | Change in Mastocytosis Activity Score (MAS) |
Time Frame: | 18 months |
Safety Issue: | |
Description: | 0 - 252 (higher values represent worse symptom outcomes) |
Measure: | Duration of Response (DOR) |
Time Frame: | 18 months |
Safety Issue: | |
Description: | Months |
Measure: | Time to Response (TTR) |
Time Frame: | 18 months |
Safety Issue: | |
Description: | Months |
Measure: | Progression Free Survival (PFS) |
Time Frame: | 18 Months |
Safety Issue: | |
Description: | Months |
Measure: | Overall Survival (OS) |
Time Frame: | 18 months |
Safety Issue: | |
Description: | Months |
Measure: | Pure Pathological Response (PPR) |
Time Frame: | 18 months |
Safety Issue: | |
Description: | Months |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Cogent Biosciences, Inc. |
Trial Keywords
- Mastocytosis
- Systemic Mastocytosis
- Advanced Mastocytosis
- Aggressive Mastocytosis
- Hematologic Neoplasms
- Mast Cell
- Mast Cell Leukemia
- Soft Tissue Neoplasms
- Neoplasms by site
- Skin Diseases
- Immune Complex Diseases
- Immune System Diseases
- Hypersensitivity
- Hematologic Diseases
- Leukemia
- Myeloid Leukemia
- Acute Myeloid Leukemia
- SM with Associated Hematologic Neoplasm
- AdvSM
- ASM
- SM-AHN
- MCL
- Neoplasm
- D816V
- KIT D816V
- AML
- bezuclastinib
- CGT9486
- CGT
- PLX
- Connective Tissue Neoplasms
Last Updated
August 9, 2021